ReviewTheranostics2026
Cell-derived biomimetic nanomedicines: Emerging theranostic platforms for precision management of atherosclerosis.
Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS), driven by complex cellular interactions, remains a leading cause of mortality worldwide. Conventional therapies often lack diseased blood vessels specificity, limiting therapy efficacy while increasing off-target toxicity. Boasting the biological advantages of cell-derived camouflages, these biomimetic nanomedicines outperform traditional drugs in intraplaque accumulation, circulation half-life and anti-AS efficacy. Current cell-derived biomimetic nanomedicines include whole-cell carriers, cell membrane-coated nanoparticles (NPs), and extracellular vesicles (EVs), all exploitable as novel platforms for plaque imaging and treatment. This review introduces the cellular mechanisms of AS pathology, examines recent advances in biomimetic strategies for AS theranostics and discusses the major barriers in clinical translation including biomaterial design, manufacturing consistency, safety evaluation, and large-scale production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.